BR112016012792A2 - Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras - Google Patents
Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladorasInfo
- Publication number
- BR112016012792A2 BR112016012792A2 BR112016012792A BR112016012792A BR112016012792A2 BR 112016012792 A2 BR112016012792 A2 BR 112016012792A2 BR 112016012792 A BR112016012792 A BR 112016012792A BR 112016012792 A BR112016012792 A BR 112016012792A BR 112016012792 A2 BR112016012792 A2 BR 112016012792A2
- Authority
- BR
- Brazil
- Prior art keywords
- biomarkers
- treatment
- methods
- predictor
- clinical sensitivity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
MÉTODOS PARA O TRATAMENTO DE CÂNCERES HEMATOLÓGICOS E O USO DE BIOMARCADORES COMO UM PREDITOR DE SENSIBILIDADE CLÍNICA A TERAPIAS IMUNOMODULADORAS. A presente invenção refere-se, em certas modalidades, a biomarcadores para o uso na previsão da sensibilidade clínica de cânceres hematológicos, tais como linfoma não de Hodgkin e uma resposta do paciente ao tratamento com um agente imunomodulador, tal como 3-(4-amino-1-oxo-1,3-di-hidro-isoindol-2-il)-piperidina-2,6-diona, que também é conhecido como lenalidomida ou Revlimid®. Também provido aqui, em certas modalidades, são métodos de tratamento ou condução dos linfomas não de Hodgkin, incluindo, mas não limitados ao linfoma difuso de grandes células B (DLBCL), usando fatores prognósticos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913046P | 2013-12-06 | 2013-12-06 | |
| PCT/US2014/068767 WO2015085160A2 (en) | 2013-12-06 | 2014-12-05 | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016012792A2 true BR112016012792A2 (pt) | 2017-08-08 |
Family
ID=53274284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016012792A BR112016012792A2 (pt) | 2013-12-06 | 2014-12-05 | Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160312292A1 (pt) |
| EP (1) | EP3077547A4 (pt) |
| JP (1) | JP2017503481A (pt) |
| KR (1) | KR20160090390A (pt) |
| AU (1) | AU2014360316A1 (pt) |
| BR (1) | BR112016012792A2 (pt) |
| CA (1) | CA2932266A1 (pt) |
| EA (1) | EA201691143A1 (pt) |
| IL (1) | IL245936A0 (pt) |
| MX (1) | MX2016007179A (pt) |
| PH (1) | PH12016501023A1 (pt) |
| WO (1) | WO2015085160A2 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160282354A1 (en) | 2013-11-08 | 2016-09-29 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| EP3077548B1 (en) | 2013-12-06 | 2021-11-10 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| ES2929883T3 (es) * | 2014-10-17 | 2022-12-02 | Stichting Maastricht Radiation Oncology Maastro Clinic | Método de análisis de imágenes que apoya la predicción del desarrollo de enfermedades de una neoplasia en un cuerpo humano o animal |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| WO2017044793A1 (en) | 2015-09-11 | 2017-03-16 | The Brigham And Women's Hospital, Inc. | Methods of characterizing resistance to modulators of cereblon |
| EP3352756A1 (en) * | 2015-09-25 | 2018-08-01 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| MX2018008421A (es) | 2016-01-08 | 2019-12-09 | Celgene Corp | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. |
| EP3674416A4 (en) * | 2017-09-29 | 2021-05-26 | Kyushu University, National University Corporation | METHOD AND KIT FOR PREDICTING THE THERAPEUTIC EFFECTIVENESS OF CHEMOTHERAPY FOR PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA |
| BR112022007386A2 (pt) * | 2019-10-21 | 2022-07-05 | Celgene Corp | Métodos para tratar um câncer hematológico e o uso de biomarcadores companheiros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2710196A1 (en) * | 2007-12-20 | 2009-07-09 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| AU2011224166B2 (en) * | 2010-03-12 | 2014-08-21 | Celgene Corporation | Methods for the treatment of non-Hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| AU2012249491B2 (en) * | 2011-04-29 | 2016-12-15 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
-
2014
- 2014-12-05 EP EP14867978.0A patent/EP3077547A4/en not_active Withdrawn
- 2014-12-05 WO PCT/US2014/068767 patent/WO2015085160A2/en active Application Filing
- 2014-12-05 EA EA201691143A patent/EA201691143A1/ru unknown
- 2014-12-05 JP JP2016536527A patent/JP2017503481A/ja active Pending
- 2014-12-05 AU AU2014360316A patent/AU2014360316A1/en not_active Abandoned
- 2014-12-05 KR KR1020167017539A patent/KR20160090390A/ko not_active Application Discontinuation
- 2014-12-05 CA CA2932266A patent/CA2932266A1/en not_active Abandoned
- 2014-12-05 MX MX2016007179A patent/MX2016007179A/es unknown
- 2014-12-05 US US15/101,866 patent/US20160312292A1/en not_active Abandoned
- 2014-12-05 BR BR112016012792A patent/BR112016012792A2/pt not_active Application Discontinuation
-
2016
- 2016-05-31 PH PH12016501023A patent/PH12016501023A1/en unknown
- 2016-05-31 IL IL245936A patent/IL245936A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12016501023A1 (en) | 2016-07-04 |
| WO2015085160A2 (en) | 2015-06-11 |
| AU2014360316A1 (en) | 2016-06-16 |
| JP2017503481A (ja) | 2017-02-02 |
| WO2015085160A3 (en) | 2015-07-30 |
| EA201691143A1 (ru) | 2016-11-30 |
| KR20160090390A (ko) | 2016-07-29 |
| US20160312292A1 (en) | 2016-10-27 |
| IL245936A0 (en) | 2016-07-31 |
| EP3077547A4 (en) | 2017-11-08 |
| MX2016007179A (es) | 2016-09-08 |
| CA2932266A1 (en) | 2015-06-11 |
| EP3077547A2 (en) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016012792A2 (pt) | Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras | |
| BR112015007184A2 (pt) | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer | |
| BR112018005295A2 (pt) | terapias com célula t car com eficácia aumentada | |
| SG10201907841UA (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| BR112015022934A2 (pt) | esteroides neuroativos, composições, e uso do mesmo | |
| BR112016018044A2 (pt) | teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer | |
| MX2022007800A (es) | Anticuerpos anti-gen de activacion de linfocitos gen-3 (lag-3) para usarse en el tratamiento de neoplasias hematologicas. | |
| NZ721866A (en) | Anti-vista antibodies and fragments | |
| BR112015004229A2 (pt) | ensaios de diagnósticos e kits para a deteção de receptor 1 do folato | |
| BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
| BR112014005427A2 (pt) | método implantado por um dispositivo de computação | |
| AR080505A1 (es) | Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores | |
| BR112017003620A2 (pt) | métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos | |
| MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
| BR112014012590A8 (pt) | Anticorpos anti-cd98 e métodos de uso dos mesmos | |
| BR112016024143A2 (pt) | tratamento de câncer | |
| WO2015094996A3 (en) | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists | |
| MX368099B (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
| MX2010006090A (es) | Biomarcadores para predecir la sensibilidad de las celulas ante compuestos inmunomoduladores durante el tratamiento de linfoma de no hodgkin. | |
| TR201907737T4 (tr) | Test numunesi desteği ve çarpışma testi aparatı ve destek kullanılarak yapısal elemanın çarpışma testi yöntemi. | |
| MX2016007903A (es) | Metodos de elaboración de perfiles de epitopos de celulas t, elaboracion de composiciones de celulas t y tratamiento de enfermedades. | |
| TR201909951T4 (tr) | Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem. | |
| CY1123698T1 (el) | Εμπλουτισμος κυκλοφορουντων κυτταρων ογκου μεσω εξαντλησης λευκων αιμοσφαιριων | |
| IL245766B (en) | Different levels in blood cell samples of emt markers for the diagnosis of cancer, in particular colon cancer (crc) and pancreatic cancer (pc) | |
| BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |